These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Anderson J; Popert RJ; Sanders K; Morgan RC; Stansfeld J; Dwyer J; Masters J; Parmar MK BJU Int; 2009 Feb; 103(4):464-9. PubMed ID: 18990168 [TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566 [TBL] [Abstract][Full Text] [Related]
9. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. Nayyar R; Sharma N; Gupta NP Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656 [TBL] [Abstract][Full Text] [Related]
10. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study. Rodrigues P; Meler A; Hering F Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233 [TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Jung K; Miller K; Wirth M; Albrecht M; Lein M Eur Urol; 2011 Apr; 59(4):604-12. PubMed ID: 21190792 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105 [TBL] [Abstract][Full Text] [Related]
15. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Zhang P; Wen F; Fu P; Yang Y; Li Q Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424 [TBL] [Abstract][Full Text] [Related]
16. [Comment to P. J. Olbert et al., page 164]. Heidenreich A Aktuelle Urol; 2009 May; 40(3):169-70. PubMed ID: 19479669 [No Abstract] [Full Text] [Related]
17. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. Joensuu TK Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260 [TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175 [TBL] [Abstract][Full Text] [Related]